Key Takeaways:
- The Professional Association for Transgender Health Aotearoa (PATHA) has filed an application for an urgent injunction to prevent the ban on new prescriptions of puberty blockers from coming into effect on December 19.
- The ban, agreed upon by the Cabinet, would prevent new prescriptions of gonadotropin-releasing hormone analogues, but would allow those already using them to continue their treatment.
- The decision has been met with controversy and criticism from clinical groups, who argue that the ban is based on politics rather than clinical evidence.
- The PATHA is seeking an urgent judicial review, claiming that the incoming regulation is "illegal and unethical".
- The ban follows a similar decision in the UK, where the NHS stopped routine access to puberty blockers for new patients following the Cass Review.
Introduction to the Controversy
The Professional Association for Transgender Health Aotearoa (PATHA) has filed an urgent legal injunction to stop the incoming ban on new prescriptions of puberty blockers to treat gender dysphoria. The ban, which is set to come into effect on December 19, was agreed upon by the Cabinet last month, citing a lack of high-quality evidence on the benefits or risks of the treatment. However, the decision has been met with controversy and criticism from clinical groups, who argue that the ban is based on politics rather than clinical evidence. The PATHA has filed an application for an urgent injunction to prevent the ban from coming into effect, claiming that the incoming regulation is "illegal and unethical".
The Decision to Ban Puberty Blockers
The decision to ban new prescriptions of puberty blockers was made following a major shift in Britain, where the National Health Service (NHS) stopped routine access to the treatment for new patients. This decision was based on the Cass Review, a four-year investigation commissioned by the NHS, which found that there was "not enough evidence to support their safety or clinical effectiveness". The review, spearheaded by pediatrician Dr. Hilary Cass, also raised concerns about the long-term impact of puberty blockers on brain development and bone development. However, the Cass Review has been met with criticism from some clinicians and academics, who argue that the report’s methodology was flawed and that it downplayed the risk of denying treatment to young people.
Criticism of the Ban
The decision to ban new prescriptions of puberty blockers has been met with widespread criticism from clinical groups, who argue that the ban is based on politics rather than clinical evidence. Dr. Rona Carroll, a GP specialist in gender affirming healthcare, stated that there was no evidence to justify the "extreme regulation", and that politicians were ignoring the advice of health professionals. The PATHA has also criticized the ban, stating that it would have a huge negative impact on the small number of young people in Aotearoa who are prescribed reversible pubertal suppression. The organization’s president, Jennifer Shields, stated that the regulations were being enacted "based on politics, not on clinical evidence or best-practice decision making".
The Path Forward
The PATHA is seeking an urgent judicial review, claiming that the incoming regulation is "illegal and unethical". The organization is arguing that the ban would subject transgender children in Aotearoa to harm, and that it is not in the best interests of children and young people who have a right to access healthcare free from discrimination. The Health Ministry has declined to comment on the matter, stating that it would not be appropriate to comment as the matter is now before the courts. The outcome of the judicial review is uncertain, but it is clear that the controversy surrounding the ban on puberty blockers is far from over.
International Context
The ban on puberty blockers in New Zealand is not an isolated incident, but rather part of a larger trend of countries tightening access and guidelines for the treatment. Sweden, Finland, and Norway have already restricted access to puberty blockers, and other countries are likely to follow suit. The Cass Review has had a significant impact on the international debate surrounding the use of puberty blockers, with some countries citing the review as evidence that the treatment is not supported by sufficient evidence. However, others have criticized the review’s methodology and argued that it downplays the risk of denying treatment to young people.
Conclusion
The ban on new prescriptions of puberty blockers in New Zealand has sparked a heated debate about the use of the treatment in the country. While the government has cited a lack of high-quality evidence as the reason for the ban, clinical groups have argued that the decision is based on politics rather than clinical evidence. The PATHA’s application for an urgent injunction is a significant development in the controversy, and the outcome of the judicial review will have important implications for the treatment of gender dysphoria in New Zealand. As the debate continues, it is clear that the use of puberty blockers is a complex and contentious issue that requires careful consideration of the evidence and the needs of young people.